CryoPort (NASDAQ:CYRX) Stock Gets Price Target Bump from KeyCorp

CryoPort (NASDAQ:CYRX) had its price objective hoisted by analysts at KeyCorp from $17.00 to $20.00 in a research note issued on Friday, Benzinga reports. The firm currently has an “overweight” rating on the stock. KeyCorp‘s target price indicates a potential upside of 4.71% from the company’s previous close.

Several other equities analysts also recently issued reports on CYRX. Roth Capital reissued a “buy” rating and set a $21.00 price target on shares of CryoPort in a report on Friday, August 7th. Guggenheim upped their price target on shares of CryoPort from $16.00 to $19.00 and gave the stock a “buy” rating in a research report on Thursday, October 1st. Weiss Ratings raised shares of CryoPort from a “sell (d)” rating to a “hold (c-)” rating in a report on Thursday, October 8th. Piper Sandler upgraded shares of CryoPort to a “buy” rating in a research report on Tuesday, October 13th. Finally, Needham & Company LLC lifted their price objective on shares of CryoPort from $19.00 to $28.00 and gave the company a “buy” rating in a research report on Friday. Seven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $21.69.

CryoPort Price Performance

NASDAQ:CYRX opened at $19.10 on Friday. CryoPort has a 12-month low of $7.61 and a 12-month high of $19.53. The firm has a market capitalization of $967.40 million, a P/E ratio of -19.69 and a beta of 1.89. The business has a 50 day simple moving average of $16.98 and a 200 day simple moving average of $13.46.

CryoPort (NASDAQ:CYRX) last issued its quarterly earnings data on Thursday, November 5th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.07). CryoPort had a negative return on equity of 8.20% and a negative net margin of 21.46%. The company had revenue of $50.22 million for the quarter, compared to the consensus estimate of $48.66 million. Research analysts anticipate that CryoPort will post -0.83 EPS for the current fiscal year.

Insider Activity

In other news, CEO Jerrell Shelton sold 28,800 shares of the stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $14.91, for a total value of $429,408.00. Following the completion of the transaction, the chief executive officer owned 1,201,814 shares of the company’s stock, valued at approximately $17,919,046.74. This represents a 2.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 9.50% of the company’s stock.

Institutional Investors Weigh In On CryoPort

Hedge funds and other institutional investors have recently modified their holdings of the stock. Wellington Management Group LLP acquired a new stake in shares of CryoPort during the second quarter worth $8,398,000. Squarepoint Ops LLC boosted its position in shares of CryoPort by 685.1% in the 2nd quarter. Squarepoint Ops LLC now owns 368,424 shares of the company’s stock valued at $5,784,000 after purchasing an additional 321,497 shares during the period. Russell Investments Group Ltd. boosted its position in shares of CryoPort by 376.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 399,047 shares of the company’s stock valued at $6,943,000 after purchasing an additional 315,343 shares during the period. Bank of New York Mellon Corp acquired a new position in shares of CryoPort in the 2nd quarter valued at $3,363,000. Finally, Granahan Investment Management LLC increased its stake in CryoPort by 475.0% in the 1st quarter. Granahan Investment Management LLC now owns 231,138 shares of the company’s stock worth $1,914,000 after purchasing an additional 190,938 shares in the last quarter. 92.90% of the stock is currently owned by institutional investors.

Trending Headlines about CryoPort

Here are the key news stories impacting CryoPort this week:

• Positive Sentiment: Third-quarter revenue rose 14% year over year to $50.2 million, topping estimates of $48.66 million. Commercial cell and gene therapy revenue grew 20%; Cryoport supported a record 788 global clinical trials and 23 commercially approved therapies. Cryoport Reports Third Quarter 2026 Financial Results
• Positive Sentiment: The company raised its full-year 2026 revenue outlook to $197 million–$199 million, a key catalyst behind the favorable reaction to results. CryoPort Shares Rise After Q3 Revenue Beat, 2026 Guidance Raise
• Positive Sentiment: Analyst actions added support: Needham raised its price target to $28 from $19 and reiterated Buy, while KeyCorp lifted its target to $20 from $17 and maintained an Overweight rating. Needham Adjusts Price Target KeyCorp Rating
• Negative Sentiment: Adjusted earnings were a loss of $0.25 per share, missing consensus estimates of a $0.18–$0.19 loss and widening from a $0.18 loss a year earlier. The earnings shortfall may temper optimism around the revenue growth and raised outlook. CryoPort Reports Q3 Loss, Tops Revenue Estimates

About CryoPort

CryoPort, Inc (NASDAQ: CYRX) provides temperature-controlled supply chain solutions for the life sciences industry. The company supports the transportation, storage and management of biological materials, including cell and gene therapies, vaccines, biologics, reproductive materials and other temperature-sensitive products.

Its offerings include cryogenic and refrigerated shipping containers, biological material storage, transportation logistics, shipment monitoring and related supply chain management services.